ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $90M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.12.2023 | Series A | $90M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 07.12.2023 | Investors pour $90M onto ARTBIO's palette less than 6 months... | ARTBIO launched less than six months ago with $23 million in seed funds, but in today’s dicey financ... | fiercebiot... |
| 07.12.2023 | ARTBIO Raises $90M in Series A Financing | ARTBIO, a Cambridge, MA- and Basel, Switzerland-based clinical-stage radiopharmaceutical company, ra... | finsmes.co... |
| - | ARTBIO | “Learn about how ARTBIO is redefining cancer care through a new class of alpha radioligand therapies... | fastfounde... |